Skip to content

Trial Summary

This study will collect data related to the management of women and men with HER2 positive metastatic breast cancer who are treated in routine clinical practice.

Acronym:

TABITHA

ACTRN/NCT /ethics:

ACTRN12615000232538

Scientific title:

Treatment of Advanced Breast Cancer in the Human Epidermal Growth Factor Receptor 2 (HER2) Positive Australian Patient

Sponsor / Cooperative group:

BioGrid Australia Ltd

Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeEarly detection, diagnosis, prognosis
PhaseAll phases
Age Range18 years and older
SexBoth
Tumour Stream Breast
Cancer StageMetastatic or Widespread
Anticipated Start DateN/A
Anticipated End DateN/A

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6140
Principal InvestigatorDr Amanda Townsend
Recruitment StatusNot Yet Recruiting